Table 5.
Effect of >10 novel surface HLA-DRB1–tFVIII peptide binding combinations on inhibitor risk
| OR (95% CI) | |
|---|---|
| Unadjusted model | 4.4 (1.4-14.0) |
| Adjusted model* | 4.1 (1.1-15.0) |
Adjusted for intensive FVIII treatment.
Likelihood Ratio Test for interaction between >10 novel peptides and intensive FVIII treatment indicated no statistically significant interaction, P = .6.